Quarterly ResultAug 4, 2026, 04:09 PM
Syndax Q2 Total Revenue Jumps 92% to $72.8M
AI Summary
Syndax Pharmaceuticals reported strong second-quarter 2026 financial results, with total revenue increasing 92% year-over-year to $72.8 million. This growth was driven by a 91% increase in Revuforj net revenue to $54.7 million and a 93% rise in Niktimvo collaboration revenue to $18.1 million. The company also expanded its pipeline with two new assets, SNDX-4321 and SNDX-62122, and anticipates key Phase 2 data readouts for axatilimab in IPF and frontline cGVHD in Q4 2026. Syndax expects to reach profitability with its current cash and anticipated revenues.
Key Highlights
- Total revenue for Q2 2026 was $72.8 million, a 92% increase year-over-year.
- Revuforj net revenue reached $54.7 million, up 91% from Q2 2025.
- Niktimvo collaboration revenue was $18.1 million, a 93% increase year-over-year.
- Net loss for Q2 2026 was $(49.4) million, compared to $(71.8) million in Q2 2025.
- Cash, cash equivalents, and investments totaled $575.1 million as of June 30, 2026.
- Anticipates topline data from Phase 2 trials of axatilimab in IPF and frontline cGVHD in Q4 2026.
- Plans IND submission for SNDX-4321 (EGFR inhibitor) by year-end 2026 and SNDX-62122 (menin inhibitor) in 2027.
Price Impact
More from SNDX